Drug-induced acute esophageal lesions and use of ciprofloxacin
Palabras clave:
Aged. Ciprofloxacin. Drug-induced esophagitis. Endoscopy.Resumen
We report the case of a 95-year-old woman who had acute esophageal lesions while being treated with oral ciprofloxacin for an acute cystitis. On day 2 of treatment, she reported retroesternal pain with a globus sensation, and presented hematemesis and melena. There was no history of gastric or esophageal disturbances. An upper digestive endoscopy showed bleeding lesions on the middle third of the esophagus. Ciprofloxacin was discontinued and a proton pump inhibitor was administered. One week later, the endoscopic aspect of the esophagus was normal. Only two cases of ciprofloxacin-induced esophageal lesions have been reported previously. A short review of this kind of esophageal injuries is presented, focusing on the main risk factors and preventive measures.Descargas
Citas
1. ABID S, MUMTAZ K, JAFRI W, HAMID S, ABBAS Z, SHAH HA et al. Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy 2005; 37: 740-744.
https://doi.org/10.1055/s-2005-870129
2. AKHTAR AJ. Oral medication-induced esophageal injury in elderly patients. Am J Med Sci 2003; 326: 133-135.
https://doi.org/10.1097/00000441-200309000-00005
3. ARORA AS, MURRAY JA. Iatrogenic esophagitis. Curr Gastroenterol Rep 2000; 2: 224-229.
https://doi.org/10.1007/s11894-000-0065-1
4. No authors listed. [Drug-induced esophageal injuries-an overview. Adverse effects of felodipine and ciprofloxacin observed during 2 years]. Lakartidningen 1990; 87: 2368-2369.
5. EMAMI MH, HAGHIGHI M, ESMAEILI A. Esophagitis caused by ciprofloxacin: a case report and review of the literature. Govaresh 2004; 9: 272-276.
6. NARANJO CA, BUSTO U, SELLERS EM, SANDOR P, RUIZ I, ROBERTS EA et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
https://doi.org/10.1038/clpt.1981.154
7. PEMBERTON J. Oesophageal obstruction and ulceration caused by oral potassium therapy. Br Heart J 1970; 32: 267-268.
https://doi.org/10.1136/hrt.32.2.267
8. KIKENDALL JW. Pill esophagitis. J Clin Gastroenterol 1999; 28: 298-305.
https://doi.org/10.1097/00004836-199906000-00004
9. LEONG RW, CHAN FK. Drug-induced side effects affecting the gastrointestinal tract. Expert Opin Drug Saf 2006; 5: 585-592.
https://doi.org/10.1517/14740338.5.4.585
10. ZOGRAFOS GN, GEORGIADOU D, THOMAS D, KALTSAS G, DIGALAKIS M. Drug-induced esophagitis. Dis Esophagus 2009; 22: 633-637.
https://doi.org/10.1111/j.1442-2050.2009.00972.x
11. O'NEILL JL, REMINGTON TL. Drug-induced esophageal injuries and dysphagia. Ann Pharmacother 2003; 37: 1675-1684.
https://doi.org/10.1345/aph.1D056
12. JASPERSEN D. Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management. Drug Saf 2000; 22: 237-249.
https://doi.org/10.2165/00002018-200022030-00007
13. KIKENDALL JW. Pill-induced esophageal injury. Gastroenterol Clin North Am 1991; 20: 835-846.
https://doi.org/10.1016/S0889-8553(21)00591-4
14. SANTOS VM, VILLAÇA RB, GOUVÊA LP, SÁ DAR. Comment on the clinical note: Acute necrotizing esophagitis in an unstable patient. An Sist Sanit Navar 2009; 32: 439-442.
https://doi.org/10.4321/S1137-66272009000500013
15. STAHLMANN R, LODE H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging 2010; 27: 193-209.
https://doi.org/10.2165/11531490-000000000-00000
16. ESCRIBANO E, CALPENA AC, GARRIGUES TM, FREIXAS J, DOMENECH J, MORENO J. Structure-absorption relationships of a series of 6-fluoroquinolones. Antimicrob Agents Chemother 1997; 41: 1 996-2000. Erratum in: Antimicrob Agents Chemother 1997; 41: 2595.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2012 Anales del Sistema Sanitario de Navarra
Esta obra está bajo una licencia internacional Creative Commons Atribución-CompartirIgual 4.0.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
